Shangqin Liu,Chengsi Gui. Megakaryocyte aplastic thrombocytopenia after CAR T-cell therapy in a patient with multiple myeloma: A case report. Oncol Transl Med, 2021, 7: 45-47.
Megakaryocyte aplastic thrombocytopenia after CAR T-cell therapy in a patient with multiple myeloma: A case report
Received:August 09, 2020  Revised:February 22, 2021
View Full Text  View/Add Comment  Download reader
KeyWord:megakaryocyte aplastic thrombocytopenia; chimeric antigen receptor (CAR) T cell therapy; multiple myeloma; case report
Author NameAffiliationE-mail
Shangqin Liu Department of Hematology, Zhongnan Hospital of Wuhan University ubeliu@aliyun.com 
Chengsi Gui Department of Hematology, Zhongnan Hospital of Wuhan University  
Hits: 3450
Download times: 4497
Abstract:
      Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment strategy for hematologic malignancies. The success of CAR T-cell therapy in treating leukemia and lymphoma has promoted its development for multiple myeloma (MM), and the initial results of CAR T cell therapy have been encouraging. CAR T-cell therapy target antigens that have been clinically evaluated in MM; these antigens include CD19, B cell maturation antigen (BCMA), CD38, and CD138. A barrier to the widespread use of CAR T-cell therapy is its toxicity, primarily cytokine release syndrome (CRS), and neurologic toxicity. This study reports a patient with refractory MM who also developed megakaryocyte aplastic thrombocytopenia after receiving CAR T-cell therapy; such a case or the unusual side effects involving medications are yet unreported. There are risks in using cyclosporine and other immunosuppressants that may lead to MM recurrence as the use of such substances is contradictory to previous treatments; therefore, we temporarily administered platelet infusion as supportive care. Thus far, the condition of the patient has been steady and the patient regularly takes blood test in the hospital.
Close